Reactivation of Silenced WT1 Transgene by Hypomethylating Agents: Implications for in vitro Modeling of Chemoimmunotherapy.
- Author:
Yong Rim KWON
1
;
Min Jung SON
;
Hye Jung KIM
;
Yoo Jin KIM
Author Information
- Publication Type:In Vitro ; Original Article
- Keywords: Wilms' tumor 1; Methylation; Transgene; Decitabine; Azacitidine
- MeSH: Azacitidine; Blotting, Western; Cell Line; Down-Regulation; Immunotherapy; Leukemia; Methylation; Models, Theoretical; Real-Time Polymerase Chain Reaction; RNA, Messenger; Transgenes; Up-Regulation; Wilms Tumor
- From:Immune Network 2012;12(2):58-65
- CountryRepublic of Korea
- Language:English
- Abstract: BACKGROUND: A cell line with transfected Wilms' tumor protein 1 (WT1) is has been used for the preclinical evaluation of novel treatment strategies of WT1 immunotherapy for leukemia due to the lack of appropriate murine leukemia cell line with endogenous WT1. However, silencing of the transgene occurs. Regarding the effects of hypomethylating agents (HMAs) on reactivation of silenced genes, HMAs are considered to be immune enhancers. METHODS: We treated murine WT1- transfected C1498 (mWT1-C1498) with increasing doses of decitabine (DAC) and azacitidine (AZA) to analyze their effects on transgene reactivation. RESULTS: DAC and AZA decreased the number of viable cells in a dose- or time-dependent manner. Quantification of WT1 mRNA level was analyzed by real-time polymerase chain reaction after mWT1-C1498 treated with increasing dose of HMA. DAC treatment for 48 h induced 1.4-, 14.6-, and 15.5-fold increment of WT1 mRNA level, compared to untreated sample, at 0.1, 1, and 10microM, respectively. Further increment of WT1 expression in the presence of 1 and 10microM DAC was evident at 72 h. AZA treatment also induced up-regulation of mRNA, but not to the same degree as with DAC treatment. The correlation between the incremental increases in WT1 mRNA by DAC was confirmed by Western blot and concomitant down-regulation of WT1 promoter methylation was revealed. CONCLUSION: The in vitro data show that HMA can induce reactivation of WT1 transgene and that DAC is more effective, at least in mWT1-C1498 cells, which suggests that the combination of DAC and mWT1-C1498 can be used for the development of the experimental model of HMA-combined WT1 immunotherapy targeting leukemia.
